Dan has 17 years experience in the biotech sector with particular focus on drug delivery and nanotechnologies for oncology. He has managed interdisciplinary R&D programmes across biology, chemistry and engineering. As well as leading Biodexa Pharmaceuticals’ exploratory oncology R&D, Dan is responsible for management of Biodexa Pharmaceuticals’ intellectual property portfolio.

Dan holds a PhD in Chemistry, an MBA from Imperial College Business School and is a Fellow of the Royal Society of Chemistry.